Trial
NCT04809766
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
Lonza Walkersville, Inc.
Condition
Metastatic Pancreatic Ductal Adenocarcinoma
Intervention
Autologous Mesothelin-specific TCR-T Cells
Why stopped
Study terminated due to end of funding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-02